ReviewFrontiers in oncology2024

mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.

Ye Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.